Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment
Alanood S Almurshedi, 1,* Hessah A Aljunaidel, 2 Bushra Alquadeib, 1 Basmah N Aldosari, 1,* Iman M Alfaqiah, 1 Salma S Almarshidy, 1 Eram KD Eltahir, 1 Amany Z Mohamoud 1 1Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 2Drug Regulatory Affairs, Novart...
Main Authors: | Almurshedi AS, Aljunaidel HA, Alquadeib B, Aldosari BN, Alfagih IM, Almarshidy SS, Eltahir EKD, Mohamoud AZ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-03-01
|
Series: | International Journal of Nanomedicine |
Subjects: | |
Online Access: | https://www.dovepress.com/development-of-inhalable-nanostructured-lipid-carriers-for-ciprofloxac-peer-reviewed-article-IJN |
Similar Items
-
Non Cystic Fibrosis Bronchiectasis-new clinical approach, management of treatment and pulmonary rehabilitation
by: Anca Maierean, et al.
Published: (2019-05-01) -
Comparison of Phospholipid-Based Particles for Sustained Release of Ciprofloxacin Following Pulmonary Administration to Bronchiectasis Patients
by: Jeffry Weers
Published: (2019-11-01) -
Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis
by: Chorepsima S, et al.
Published: (2018-11-01) -
Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies
by: Mohammed Elmowafy, et al.
Published: (2021-09-01) -
Noncystic fibrosis bronchiectasis: Is it an orphan disease?
by: Mobaireek Khalid
Published: (2007-01-01)